EULAV Asset Management’s West Pharmaceutical WST Stock Holding History

EULAV Asset Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-104,616	Closed	-$28.8M	–	148
2025 Q4	$28.8M	Hold	104,616	–	–	0.77%	42
2025 Q3	$27.4M	Sell	104,616 -33,000	-24%	-$8.02M	0.64%	53
2025 Q2	$30.1M	Hold	137,616	–	–	0.71%	41
2025 Q1	$30.8M	Sell	137,616 -7	-0%	-$1.93K	0.76%	42
2024 Q4	$45.1M	Hold	137,623	–	–	1.09%	29
2024 Q3	$41.3M	Buy	137,623 +2	+0%	+$612	1.01%	30
2024 Q2	$45.3M	Buy	137,621 +9,000	+7%	+$3.18M	1.23%	25
2024 Q1	$50.9M	Buy	128,621 +5	+0%	+$1.85K	1.4%	22
2023 Q4	$45.3M	Buy	128,616 +14,600	+13%	+$5.17M	1.4%	19
2023 Q3	$42.8M	Buy	114,016 +45,500	+66%	+$17.6M	1.56%	14
2023 Q2	$26.2M	Buy	68,516 +57,416	+517%	+$20.5M	0.98%	38
2023 Q1	$3.85M	Buy	+11,100	New	+$3.24M	0.15%	127

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EULAV Asset Management's WST Position: Q1 2026 in Review

EULAV Asset Management sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 104,616 shares — an estimated $28.8M sold.

EULAV Asset Management first reported a position in WST in Q1 2023 and held it in 12 quarters. The position peaked at $50.9M in Q1 2024. 755 funds tracked by Wall St. Rank hold WST as of Q1 2026.

EULAV Asset Management reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
EULAV Asset Management sold 104,616 West Pharmaceutical shares in Q1 2026, an estimated $28.8M.
EULAV Asset Management first reported a position in West Pharmaceutical in Q1 2023 and held it in 12 quarters.
EULAV Asset Management's West Pharmaceutical position peaked at $50.9M in Q1 2024.
755 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on EULAV Asset Management's 13F filing for Q1 2026, filed 7 May 2026.